Early trials of Ebola vaccine show immune response

Small, phase I trials in Africa and Europe of an experimental vaccine against Ebola virus disease have shown an immune response in all of the healthy adults vaccinated, preliminary results reported in the New England Journal of Medicine have shown.1

The Zaire variant candidate vaccine rVSV-ZEBOV uses live recombinant vesicular stomatitis virus (rVSV), a livestock disease that generally causes no or only mild illness in humans, to carry DNA from Zaire ebolavirus with the aim of stimulating …